Difference between revisions of "Volunteer Assignments and Opportunities"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
VisualWikitext
[unchecked revision][checked revision]
 
(392 intermediate revisions by 13 users not shown)
Line 1: Line 1:
 +
Welcome!   
 +
 +
 +
We are creating content for all diseases with genetic findings in the current WHO Classification of Tumours books.  Please join the effort!   
 +
 +
 +
To volunteer: 
 +
 +
#Select a link in the table to your book(s) of interest to view specific authorship opportunities.  Additional books are in the process of being added.
 +
#'''[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]''' with your disease page of interest.  You will be connected with an Associate Editor to help guide you through the process.
 +
#Complete the brief '''[https://mms.cancergenomics.org/members/form.php?orgcode=CGC&fid=3830649 <u>Volunteer Form</u>]''' to receive your log-in credentials.  Information on [[Description of CCGA Roles|<u>Authorship and Other Roles</u>]] with the CCGA is available.
 +
  
 
{| class="wikitable"
 
{| class="wikitable"
 +
|+BOOKS WITH CONTENT IN PROGRESS
 +
!Book Name
 +
!Book Edition
 +
!Book Acronym
 
|-
 
|-
−
|'''Disease'''||'''Page Type'''||'''Author'''||'''Associate Editor'''
+
|[[HAEM5:Volunteer Assignments and Opportunities|WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues]]
−
!Author Content (Pending or Complete)
+
|5th
−
!Editor Reviewed (Date)
+
|HAEM5
 
|-
 
|-
−
|Myeloproliferative Neoplasms (MPN)||'''''Overview'''''|| ||Fabiola Quintero-Rivera (FQR)
+
|[[CNS5:Volunteer Assignments and Opportunities|WHO Classification of Tumours of the Central Nervous System]]
−
|
+
|5th
−
|
+
|CNS5
 
|-
 
|-
−
|Chronic Myeloid Leukemia (CML), BCR-ABL1-Positive||Disease
+
|[[GTS5:Volunteer Assignments and Opportunities|WHO Classification of Genetic Tumour Syndromes]]
−
| ||FQR
+
|5th
−
|
+
|GTS5
−
|
 
 
|-
 
|-
−
|Chronic Neutrophilic Leukemia (CNL)||Disease
+
|[[BRST5:Volunteer Assignments and Opportunities|WHO Classification of Tumours of the Breast]]
−
| ||FQR
+
|5th
−
|
+
|BRST5
−
|
 
 
|-
 
|-
−
|Polycythaemia Vera (PV)||Disease
+
|[[STBT5:Volunteer Assignments and Opportunities|WHO Classification of Soft Tissue and Bone Tumours]]
−
| ||FQR
+
|5th
−
|
+
|STBT5
−
|
+
|}
−
|-
+
 
−
|Primary Myelofibrosis (PMF)||Disease
+
 
−
| ||FQR
+
{| class="wikitable"
−
|
+
|+BOOKS COMING SOON
−
|
+
!Book Name
−
|-
+
!Book Edition
−
|Essential Thrombocythaemia (ET)||Disease
+
!Book Acronym
−
| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Chronic Eosinophilic Leukemia, Not Otherwise Specified||Disease
 
−
| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Myeloproliferative Neoplasm (MPN), Unclassifiable||Disease
 
−
| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Mastocytosis||'''''Overview'''''|| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Cutaneous Mastocytosis||Disease
 
−
| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Systemic Mastocytosis||Disease
 
−
| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Mast Cell Sarcoma||Disease
 
−
| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement  of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2||'''''Overview'''''|| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement||Disease|| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement||Disease|| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement||Disease|| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Myeloid/Lymphoid Neoplasms with PCM1-JAK2||Disease|| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)||'''''Overview'''''|| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Chronic Myelomonocytic Leukemia (CMML)||Disease|| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative||Disease|| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Juvenile Myelomonocytic Leukemia (JMML)||Disease|| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Myelodysplastic/Myeloproliferative Neoplasms with Ring  Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)||Disease|| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN),  Unclassifiable||Disease|| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Myelodysplastic Syndromes (MDS)||'''''Overview'''''|| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Myelodysplastic Syndrome (MDS) with Single Lineage Dysplasia||Disease|| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)||Disease|| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage  Dysplasia||Disease|| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Myelodysplastic syndrome with multilineage  dysplasiaMyelodysplastic Syndrome (MDS) with Multilineage Dysplasia||Disease|| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Myelodysplastic Syndrome (MDS) with Excess Blasts||Disease|| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Myelodysplastic Syndrome (MDS) with Isolated del(5q)||Disease|| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Myelodysplastic Syndrome (MDS), Unclassifiable||Disease|| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
|Refractory Cytopenia of Childhood||Disease|| ||FQR
 
−
|
 
−
|
 
−
|-
 
−
| || || ||
 
−
|
 
−
|
 
−
|-
 
−
|Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms||'''''Overview'''''|| ||Jennelle Hodge (JH)
 
−
|
 
−
|
 
−
|-
 
−
|Myeloid Neoplasms with Germline Predisposition||'''''Overview'''''|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute Myeloid  Leukaemia with Germline CEBPA Mutation||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Myeloid Neoplasms  with Germline DDX41 Mutation||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Myeloid Neoplasms  with Germline RUNX1 Mutation||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Myeloid Neoplasms  with Germline ANKRD26 Mutation||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Myeloid Neoplasms  with Germline ETV6 Mutation||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Myeloid Neoplasms  with Germline GATA2 Mutation||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute Myeloid Leukemia (AML) with Recurrent Genetic  Abnormalities||'''''Overview'''''|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute Myeloid  Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute Myeloid  Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute Promyelocytic  Leukemia (APL) with PML-RARA||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute Myeloid  Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute Myeloid  Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute Myeloid  Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute Myeloid  Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute Myeloid  Leukemia (AML) with BCR-ABL1||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute Myeloid  Leukemia (AML) with Mutated NPM1||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute Myeloid  Leukemia (AML) with Biallelic Mutations of CEBPA||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute Myeloid  Leukemia (AML) with Mutated RUNX1||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Therapy-Related Myeloid Neoplasms||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute Myeloid Leukemia (AML), Not Otherwise Specified||'''''Overview'''''|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute Myeloid  Leukemia (AML) with Minimal Differentiation||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute Myeloid  Leukemia (AML) without Maturation||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute Myeloid  Leukemia (AML) with Maturation||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute  Myelomonocytic Leukemia||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute Monoblastic  and Monocytic Leukemia||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Pure Erythroid  Leukemia||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute  Megakaryoblastic Leukemia (AMKL)||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute Basophilic  Leukemia||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute Panmyelosis  with Myelofibrosis||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Myeloid Sarcoma||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Myeloid Proliferations Associated with Down Syndrome||'''''Overview'''''|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Transient Abnormal  Myelopoiesis (TAM) Associated with Down Syndrome||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Myeloid Leukemia  Associated with Down Syndrome||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Blastic Plasmacytoid Dendritic Cell Neoplasm||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute Leukemias of Ambiguous Lineage||'''''Overview'''''|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Acute  Undifferentiated Leukemia||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Mixed Phenotype  Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Mixed Phenotype  Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Mixed Phenotype  Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|Mixed Phenotype  Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|??Mixed-Phenotype  Acute Leukaemia, Not Otherwise Specified (NOS), Rare Types||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
|??Acute Leukaemias  of Ambiguous Lineage, Not Otherwise Specified (NOS)||Disease|| ||JH
 
−
|
 
−
|
 
−
|-
 
−
| || || ||
 
−
|
 
−
|
 
−
|-
 
−
|Precursor Lymphoid Neoplasms||'''''Overview'''''|| ||Yassmine Akkari (YA)
 
−
|
 
−
|
 
−
|-
 
−
|B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic  Abnormalities||'''''Overview'''''|| ||YA
 
−
|
 
−
|
 
−
|-
 
−
|B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2);  BCR-ABL1||Disease|| ||YA
 
−
|
 
−
|
 
−
|-
 
−
|B-Lymphoblastic  Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged||Disease|| ||YA
 
−
|
 
−
|
 
−
|-
 
−
|B-Lymphoblastic  Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease|| ||YA
 
−
|
 
−
|
 
−
|-
 
−
|B-Lymphoblastic  Leukemia/Lymphoma with Hyperdiploidy||Disease|| ||YA
 
−
|
 
−
|
 
−
|-
 
−
|B-Lymphoblastic  Leukemia/Lymphoma with Hypodiploidy||Disease|| ||YA
 
−
|
 
−
|
 
−
|-
 
−
|B-Lymphoblastic  Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3||Disease|| ||YA
 
−
|
 
−
|
 
−
|-
 
−
|B-Lymphoblastic  Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1||Disease|| ||YA
 
−
|
 
−
|
 
−
|-
 
−
|B-Lymphoblastic  Leukemia/Lymphoma, BCR-ABL1-Like||Disease|| ||YA
 
−
|
 
−
|
 
−
|-
 
−
|B-Lymphoblastic  Leukemia/Lymphoma with iAMP21||Disease|| ||YA
 
−
|
 
−
|
 
−
|-
 
−
|B-Lymphoblastic  Leukemia/Lymphoma, Not Otherwise Specified||Disease|| ||YA
 
−
|
 
−
|
 
−
|-
 
−
|T-Lymphoblastic Leukemia/Lymphoma||'''''Overview'''''|| ||YA
 
−
|
 
−
|
 
−
|-
 
−
|Early T-Cell Precursor Lymphoblastic Leukemia||Disease|| ||YA
 
−
|
 
−
|
 
−
|-
 
−
|NK-Lymphoblastic Leukemia/Lymphoma||Disease|| ||YA
 
−
|
 
−
|
 
−
|-
 
−
| || || ||
 
−
|
 
−
|
 
−
|-
 
−
|Mature B-Cell Neoplasms||'''''Overview'''''|| ||Snehal Patel (SP)
 
−
|
 
−
|
 
−
|-
 
−
|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease|| ||SP
 
−
|
 
−
|
 
−
|-
 
−
|       Monoclonal B-cell  Lymphocytosis||Disease|| ||SP
 
−
|
 
−
|
 
−
|-
 
−
|B-cell Prolymphocytic Leukemia||Disease|| ||SP
 
−
|
 
−
|
 
−
|-
 
−
|Splenic Marginal Zone Lymphoma||Disease|| ||SP
 
−
|
 
−
|
 
−
|-
 
−
|Hairy Cell Leukemia||Disease|| ||SP
 
−
|
 
−
|
 
−
|-
 
−
|Splenic B-cell Lymphoma/Leukemia, Unclassifiable||'''''Overview'''''|| ||SP
 
−
|
 
−
|
 
−
|-
 
−
|    Splenic Diffuse Red  Pulp Small B-cell Lymphoma||Disease|| ||SP
 
−
|
 
−
|
 
−
|-
 
−
|    Hairy Cell Leukemia  Variant||Disease|| ||SP
 
−
|
 
−
|
 
−
|-
 
−
|Lymphoplasmacytic Lymphoma||Disease|| ||SP
 
−
|
 
−
|
 
−
|-
 
−
|   Waldenstrom  Macroglobulinemia||Disease|| ||SP
 
−
|
 
−
|
 
−
|-
 
−
|IgM Monoclonal Gammopathy of Undetermined Significance||Disease|| ||SP
 
−
|
 
−
|
 
−
|-
 
−
|Heavy Chain Diseases||'''''Overview'''''|| ||SP
 
−
|
 
−
|
 
−
|-
 
−
|    Mu Heavy Chain  Disease||Disease|| ||SP
 
−
|
 
−
|
 
−
|-
 
−
|   Gamma Heavy Chain  Disease||Disease|| ||SP
 
−
|
 
−
|
 
−
|-
 
−
|    Alpha Heavy Chain  Disease||Disease|| ||SP
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
−
|-
 
−
|Example||Example|| ||Example
 
−
|
 
−
|
 
 
|-
 
|-
−
|Example||Example|| ||Example
+
|[[DIG5:Volunteer Assignments and Opportunities|WHO Classification of Digestive System Tumours]]
−
|
+
|5th
−
|
+
|DIG5
 
|-
 
|-
−
|Example||Example|| ||Example
+
|[[EYE5:Volunteer Assignments and Opportunities|WHO Classification of Eye and Orbit Tumours]]
−
|
+
|5th
−
|
+
|EYE5
 
|-
 
|-
−
|Example||Example|| ||Example
+
|[[SKIN5:Volunteer Assignments and Opportunities|WHO Classification of Skin Tumours]]
−
|
+
|5th
−
|
+
|SKIN5
 
|-
 
|-
−
|Example||Example|| ||Example
+
|[[HAN5:Volunteer Assignments and Opportunities|WHO Classification of Head and Neck Tumours]]
−
|
+
|5th
−
|
+
|HAN5
 
|-
 
|-
−
|Example||Example|| ||Example
+
|[[ENDO5:Volunteer Assignments and Opportunities|WHO Classification of Endocrine and Neuroendocrine Tumours]]
−
|
+
|5th
−
|
+
|ENDO5
 
|-
 
|-
−
|Example||Example|| ||Example
+
|[[MALE5:Volunteer Assignments and Opportunities|WHO Classification of Urinary and Male Genital Tumours]]
−
|
+
|5th
−
|
+
|MALE5
 
|-
 
|-
−
|Example||Example|| ||Example
+
|[[PEDS5:Volunteer Assignments and Opportunities|WHO Classification of Paediatric Tumours]]
−
|
+
|5th
−
|
+
|PEDS5
 
|-
 
|-
−
|Example||Example|| ||Example
+
|[[THOR5:Volunteer Assignments and Opportunities|WHO Classification of Thoracic Tumours]]
−
|
+
|5th
−
|
+
|THOR5
 
|-
 
|-
−
|Example||Example|| ||Example
+
|[[FEMA5:Volunteer Assignments and Opportunities|WHO Classification of Female Genital Tumours]]
−
|
+
|5th
−
|
+
|FEMA5
 
|}
 
|}

Latest revision as of 12:29, 27 June 2024

Welcome!


We are creating content for all diseases with genetic findings in the current WHO Classification of Tumours books. Please join the effort!


To volunteer:

  1. Select a link in the table to your book(s) of interest to view specific authorship opportunities. Additional books are in the process of being added.
  2. Contact us with your disease page of interest. You will be connected with an Associate Editor to help guide you through the process.
  3. Complete the brief Volunteer Form to receive your log-in credentials. Information on Authorship and Other Roles with the CCGA is available.


BOOKS WITH CONTENT IN PROGRESS
Book Name Book Edition Book Acronym
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 5th HAEM5
WHO Classification of Tumours of the Central Nervous System 5th CNS5
WHO Classification of Genetic Tumour Syndromes 5th GTS5
WHO Classification of Tumours of the Breast 5th BRST5
WHO Classification of Soft Tissue and Bone Tumours 5th STBT5


BOOKS COMING SOON
Book Name Book Edition Book Acronym
WHO Classification of Digestive System Tumours 5th DIG5
WHO Classification of Eye and Orbit Tumours 5th EYE5
WHO Classification of Skin Tumours 5th SKIN5
WHO Classification of Head and Neck Tumours 5th HAN5
WHO Classification of Endocrine and Neuroendocrine Tumours 5th ENDO5
WHO Classification of Urinary and Male Genital Tumours 5th MALE5
WHO Classification of Paediatric Tumours 5th PEDS5
WHO Classification of Thoracic Tumours 5th THOR5
WHO Classification of Female Genital Tumours 5th FEMA5
Retrieved from "https://ccga.io/index.php?title=Volunteer_Assignments_and_Opportunities&oldid=14522"